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Abstract. Simulation studies are useful for evaluating and developing statistical meth-
ods for the analyses of complex problems. Performance of methods may be affected by
multiple complexities present in real scenarios. Generating sufficiently realistic data for
this purpose, however, can be challenging. Our study of the comparative effectiveness of
HIV protocols on the risk of cardiovascular disease – involving the longitudinal assess-
ment of HIV patients – is such an example. The correlation structure across covariates
and within subjects over time must be considered as well as right-censoring of the out-
come of interest, time to myocardial infarction. A challenge in simulating the covariates
is to incorporate a joint distribution for variables of mixed type – continuous, binary or
polytomous. An additional challenge is incorporating within-subject correlation where
some variables may vary over time and others may remain static. To address these issues,
we extend the work of Demirtas and Doganay (2012). Identifying a model from which to
simulate the right-censored outcome as a function of these covariates builds on work de-
veloped by Sylvestre and Abrahamowicz (2007). In this paper, we describe a cohesive and
user-friendly approach accompanied by R code to simulate comparative effectiveness stud-
ies with right-censored outcomes that are functions of time-varying covariates.
Keywords: simulation, correlated covariates, right-censored outcomes (or time-to-event
outcomes), time-varying covariates, longitudinal studies.
1 Introduction
Simulation studies are often relied upon to demonstrate or evaluate properties of statis-
tical methods when theoretical properties may be intractable. When these properties are
well characterized, they can be used with confidence.
For example, while performing a comparative effectiveness study of antiretroviral ther-
apies where the goal was to understand the comparative risk of cardiovascular disease
among patients with HIV, co-authors of this team faced complex issues with missing data
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in a setting where many practical challenges had not yet been studied. One solution was
to explore properties of estimators (bias and efficiency) across multiple methods for han-
dling missing data under various conditions of missingness in a study that simulated a
similarly complex longitudinal setting. In order to ensure confidence in the findings, the
study should generate data that reflect those challenges encountered in the motivating
data set including how missingness was induced. In addition, other aspects of the under-
lying data should include: 1) variables that were correlated within a subject over time;
2) variables that were correlated across subjects; 3) variables of mixed type (continuous,
binary, and categorical); 4) an outcome that was right-censored; and, 5) subjects with
varying length of follow-up.
In this paper, we present our methodology for simulating comparative effectiveness stud-
ies that, although developed with a specific motivating data set in mind, can be used to
realistically simulate any comparative effectiveness study with a right-censored outcome.
We illustrate its use through one simulation study that closely mimics a real study, main-
taining interrelationships among variables and across subjects. Our methods can be used
in whole or in part, as needed, and we demonstrate their use in a power calculation for a
comparative effectiveness study.
The paper is organized as follows. Section 2 presents our motivating data set, used in a
comparative effectiveness study of antiretroviral therapies and cardiovascular disease. In
Section 3, we provide background on the methods used in our approach, which is pre-
sented in Section 4. In Section 5, we evaluate the performance of our algorithm using
commonly accepted accuracy and precision measures. In Section 6, we illustrate the util-
ity of our approach for conducting a power calculation for a comparative effectiveness
study. We provide a discussion and concluding remarks in Section 7.
2 Motivating Study
Our work is motivated by a comparative effectiveness study of the risk of antiretroviral
therapies (ART) on cardiovascular disease in US veterans with HIV. To address questions
about comparative effectiveness, data from the Veterans Health Administration Clini-
cal Case Registry (CCR) were used to create a longitudinal data set that compiled de-
mographic, diagnostic, therapeutic, and health care utilization data on all HIV-infected
patients from all VHA facilities [1]. The final cohort included 24,510 HIV-infected pa-
tients from January 1996 through December 2009 exposed to at least one antiretroviral
drug during that time period. The outcome of interest was the occurrence of any cardio-
vascular event including MI, stroke, or cardiovascular procedures such as percutaneous
coronary intervention and coronary artery bypass surgery. Subjects were followed from
the date of the first positive HIV lab test or first ART prescription until the event of in-
terest, death, or last documented activity in the CCR. Subjects who did not develop the
event of interest by the end of the study period (December 31, 2009) or who died dur-
ing the study period without experiencing the event were censored. The exposures of in-
terest were indicators of current use of each of 15 antiretroviral medications. These were
coded as time-varying indicators, allowing for a new record to be created every time there
was a medication switch. Time-invariant covariates included age, sex, and race (coded as
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white, black, and other). Time-varying covariates included body mass index (BMI) and
viral load (VL). These were defined for those periods specified by changes in exposures
to the drugs of interest. Because this data set – created from multiple sources including
pharmacy data, billing data, and clinical records – posed unique challenges to the analysis
while also representing how many comparative effectiveness studies are derived, we aimed
to create a simulation tool that could maintain many of its complexities.
3 Background
In this section, we give an overview of the methods that provide the backbone of our ap-
proach for simulating studies that reflect our motivating data set.
3.1 Generation of Time-Varying Exposures and other Covariates
We used methods found in the literature to generate the covariates and exposure vari-
ables. Specifically, we rely on the algorithm developed by Demirtas and Doganay to gen-
erate correlated binomial and normal data implemented in the R package binnor [2, 3].
In this algorithm, the authors combined the framework of Emrich and Piedmonte to gen-
erate correlated binary data with an algorithm that generates multivariate normal data
[4, 5]. It requires the user to provide marginal characteristics such as means and variances
as well as the association structure through correlations among all variables. These can
be chosen arbitrarily or informed by a motivating data set. In essence, the mechanism
assumes that all variables follow a multivariate normal density, but that some will be di-
chotomized. The algorithm then computes an overall correlation matrix that allows the
generation of a multivariate normal distribution with pre-specified correlations. Binary
variables are dichotomized by limits that are computed from the marginal proportions
provided. See Demirtas and Doganay for more details [2].
We generated categorical data from a multinomial logistic regression and imposed a linear
pattern over time within a subject on certain variables through the use of mixed effects
models. Figure 1 depicts the full algorithm; the various components will be described in
more detail in Section 4.1.
3.2 Generation of Outcome
Several methods to generate survival times that follow a Cox model with time-varying co-
variates have been proposed in the literature (see Austin, Sylvestre, and Abrahamowicz)
[6, 7, 8]. Of these, there are two methods that are relevant for our work in that they al-
low an arbitrary number of time-varying covariates with easy implementation. The first
is a method developed by Zhou and implemented by Hendry [9, 10]. Zhou showed that
right-censored outcomes can be generated from a transformation of piecewise exponential
random variables, where the hazard is assumed constant within a time interval but can
vary across time intervals that are defined by changes in the covariates. Although promis-
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Figure 1: Description of the covariate generation algorithm. Boxes are color coded to
show the output of each of the 3 steps. In step 1 (red), the algorithm outputs static vari-
ables and individual subject parameters; in step 2 (green), it outputs individual observa-
tions for each subject’s time-varying variables; and, in step 3 (blue), it generates the poly-
tomous variable. All user inputs are shown in pink boxes. Boxes with a dashed outline
show internal checks.
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ing, we found that the current implementation of the algorithm created by Hendry can be
biased in the presence of covariates that are correlated within a subject [11]. Hence, our
data generating process relies on the second method – proposed by Sylvestre and Abra-
hamowicz and implemented in the R package permalgo [7, 12]. It is a permutation-based
algorithm first introduced by Abrahamowicz et al., described in detail by MacKenzie and
Abrahamowicz, and evaluated for use with time-varying covariates by Sylvestre and Abra-
hamowicz [8, 13, 7].
The Sylvestre and Abrahamowicz algorithm differs from many standard approaches that
simulate structured random data from analytic expressions of a statistical model. Instead,
this algorithm requires one to first specify survival times, independent covariates, and
their relationship. From this, the independently generated times are matched to covari-
ates, one-to-one, based on a permutation probability law derived from the partial likeli-
hood of the Cox proportional hazards model [8, 13]. The algorithm, also depicted in Fig-
ure 2, consists of 5 main steps:
1. Generate N survival times Ti, i = 1, . . . , N from some user-specified distribution,
assumed to represent the marginal distribution of survival times in the entire popu-
lation;
2. Independently from the survival times, generate N censoring times Ci, i = 1, . . . , N ,
also from some user-specified distribution;
3. For each i, define the last observed time, t∗i = min(Ti, Ci) and an indicator of non-
censoring, δ∗i = I{Ti < Ci}. Sort (t∗i , δ∗i ) such that t∗i ≤ t∗i+1;
4. Provide (or generate) N matrices with p time-invariant and time-varying covariates
and m rows that represent intervals of follow-up time. Define Xs(t) as the vector of
covariates for subject s at time t;
5. Assign a time T to each subject s. Start from earliest observed time t∗1 and ran-
domly assign each pair (t∗i , δ
∗
i ) to a vector of current covariate values Xs(t
∗
i ), s =
1, . . . , N ; Define the risk set for time t∗i , Ri, as the vector of covariates at time t
∗
i for
all the individuals not yet assigned a time T . The assignment depends on whether
t∗i is a censoring time or not:
5.1. If t∗i is a censoring time, δ
∗
i = 0, then select an individual at random from Ri
with probability pi = 1/size(Ri);
5.2. If subject has the event, δ∗i = 1, then sample individuals from Ri with proba-
bility
ps,t∗i =
exp[β
′
xs(t
∗
i )]∑
j∈Ri exp[β
′xj(t∗i )]
(1)
The sampled individual is removed from further consideration, i.e. from Ri, and
the algorithm moves to the next largest event time and repeats the procedure. The
algorithm proceeds until all survival times have been matched to an individual.
5
Figure 2: Description of the algorithm to generate outcome: survival times that follow a
Cox model with time-varying covariates. User inputs are shown in pink boxes.
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4 Our Approach to Simulating Studies Using an External
Data Source
4.1 Simulation of Covariates
Our approach to simulating covariates is designed to capture several common features of
comparative effectiveness data: 1) covariates should be correlated both across variables at
a given time point and within each subject over time; 2) certain variables should change
over time according to specified trajectories; and 3) covariates can include at least one
multi-level categorical variable (e.g., race). Maintaining correlation structure in the pres-
ence of these complex covariates is an unresolved challenge that we addressed using the
algorithm by Demirtas and Doganay [2]. Full algorithm descriptions for generation of co-
variates and generation of outcome are depicted in Figure 1 and Figure 2, respectively.
Based on the motivating dataset, we aimed to realistically simulate correlated covariates,
comprising eight continuous variables: age, BMI, CD4 count, systolic and diastolic blood
pressure (BPS and BPD, respectively), HDL and LDL cholesterol and triglycerides; 16 bi-
nary variables (1 indicating sex and 15 indicating whether a subject was currently taking
a given drug); and, 1 categorical variable: race (defined as black, white or other). All con-
tinuous covariates were simulated as normally distributed random variables, a simplifying
assumption justified by empirical distributions in the motivating data set. For 4 of the 8
continuous variables (BMI, LDL, HDL, and CD4 count) we additionally allowed for linear
time effects within a subject, modeled using random slopes generated for each subject.
A central challenge of simulating repeated-measures data is to adequately capture both
the across- and within-subject correlation and marginal structures. To address this prob-
lem, we used a two-level simulation process. In Step 1 (see Section 4.1.1), we used pop-
ulation parameters estimated across subjects to generate subject-specific random effects,
resulting in a single row per subject. In Step 2 (see Section 4.1.2), we expanded each sub-
ject’s data longitudinally by generating individual observations around these subject-level
random effects. For example, in order to generate triglycerides, in Step 1, we sampled
values from a Normal distribution with mean and standard deviation equal to the popula-
tion mean and standard deviation of triglycerides found in the motivating data set to rep-
resent the subject-specific random effect. Then, for each subject, we generated repeated
observations from another Normal distribution with mean equal to that of the values gen-
erated in Step 1.
Special considerations were needed to simulate drug status indicator variables, for which
both 1) the overall proportion of ever-users of each drug and 2) the proportion of obser-
vations in which the user was currently on the drug (among ever-users) most closely re-
sembled the motivating dataset. We explicitly parameterized both considerations by first
simulating two variables for each of the 15 drugs: a binary variable corresponding to each
subject’s ever-use status (“exposed”) and a continuous variable corresponding to a sub-
ject’s proportion of observations the drug had been prescribed (“with exposure”), con-
ditional on a subject being exposed. These two variables were then used to simulate the
final drug status indicators for each time point.
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Throughout, we use capital Greek letters to denote population parameters specified based
on estimates from the motivating data set, capital Roman letters to denote subject-specific
random effects generated in Step 1, and lowercase Roman letters to denote individual ob-
servations generated in Step 2.
4.1.1 Step 1: Simulation of Subject-Specific Random Effects
In Step 1, we jointly simulated continuous and binary variables with joint correlation
structure Σa, the across-subject correlation matrix derived from the correlations observed
in the motivating data set (computed as Pearson correlations between all variables). The
result was a dataset with a single row for each of N subjects (Table 1).
Table 1: Example of data generated in Step 1: generate subject-specific means.
Subject ID Male Age BMI Triglycerides Exposed to Abacavir Proportion of records
(yes/no) indicating Abacavir use
(“exposed”) (“with exposure”)
1 1 25 22 88 1 0.3
2 0 50 30 120 0 0.1
3 1 40 25 100 1 0.2
Normally Distributed Random Variables. A total of 27 variables were simulated in
this step as Normally distributed random variables: the 8 continuous variables of interest,
4 subject-specific slopes for the continuous variables with linear time effects, and the 15
variables representing the proportions of observations indicating drug exposure use (“with
exposure”). To allow simultaneous simulation of binary and continuous variables (thus
accurately capturing their intercorrelations), we assumed the latter followed a Normal
distribution.
In general, we simulated all normally distributed random variables as:
Mjs ∼ N(µj , σj) (2)
where Mjs is the mean of variable j for subject s, µj is the population mean and σj is the
population standard deviation of variable j, the across-subject standard deviation. For
the variables representing the proportion of observations (“with exposure”), we estimated
the population standard deviation as:
σj =
√
µj(1− µj)
N
(3)
We simulated slopes for the linear time-varying variables centered around 0 as:
Sjs ∼ N(0, σSj ) (4)
where σSj is a pre-specified standard deviation.
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Binary Variables. There were 16 binary variables in Step 1, including 15 ever-use in-
dicators and 1 additional time-static binary variable of interest (e.g., sex) that was to re-
main static within a subject. We simulated all binary variables as:
Ijs ∼ Bern(pj) (5)
where Ijs is the binary indictor for variable j and subject s, and pj is the estimated pop-
ulation proportion (“with exposure”, or male) for variable j.
Intermediary Housekeeping Step. Before the variables generated in Step 1 can be
used to generate within-individual observations in Step 2, several “housekeeping” pro-
cedures were necessary. At the end of Step 1, the data set contained “exposed” indica-
tors as well as “with exposure” proportions for each drug. Before proceeding to Step 2,
in which the “with exposure” proportions alone were used to generate within-individual
observations, the “exposed” indicators were used to set the “with exposure” proportion to
0 for all subjects assigned to never-use (exposed=0). The “exposed” indicators were then
discarded. Additionally, as the “with exposure” variables were generated from a Normal
distribution, they could contain values outside the range of [0,1]. In these cases, out-of-
bound values were set to the nearest bound (0 or 1).
In cases where the “with exposure” proportion had been set to 0 or 1, the corresponding
non-diagonal entries of the within-subject correlation matrix (Σw) were overwritten to 0.
Moreover, entries of Σw may be out of bounds imposed by the maximum magnitude of
correlation allowable between two variables when one is binary. In these cases, the entry
was overwritten to the closest bound, defined by subject-specific parameters for the den-
sity of the binary variable (Table 2).
Table 2: Example of data generated in Step 1 after “housekeeping” procedures.
Subject ID Male Age BMI Triglycerides Exposed to Abacavir Proportion of records
(yes/no) indicating Abacavir use
(“exposed”) (“with exposure”)
1 1 25 22 88 1 0.3
2 0 50 30 120 0 0
3 1 40 25 100 1 0.2
4.1.2 Step 2: Simulation of Individual Observations within Each Subject
In Step 2, we used the subject-specific random effects generated in Step 1 jointly with
the correlation structure Σw to simulate data for each subject. The use of a new corre-
lation matrix (distinct from matrix Σa from Step 1) allows the correlation structure of
individual observations within a subject to be controlled independently from the corre-
lation structure across variables and subjects. This simulation process occurred once for
each subject.
Normally Distributed Random Variables. Within each subject, we generated indi-
vidual observations for the 4 continuous variables of interest that do not vary as a func-
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tion of time as:
xjst ∼ N(Mjs, σ′js) (6)
where xjst represents the value of variable j for subject s at time t. Mjs is the mean ob-
tained in Step 1 and σ
′
js is the within-subject standard deviation of variable j (fixed across
all subjects and equal to 1/3 of the population standard deviation, σ
′
j).
We generated the 5 continuous variables that vary as a function of time as:
xjst ∼ N(Mjs + Sjs ∗ t, σ′j) (7)
where σ
′
j is the error standard deviation for variable j.
Binary Variables. We simulated 15 time-varying indicators for current exposure to drug
as:
xjst ∼ Bern(Mjs) (8)
The remaining binary variable, sex, was static. Therefore the indicator for sex – gener-
ated from Step1 – was expanded to be a vector constant over the number of observations
within a subject. Table 3 shows an example of what the data may look like at the end of
this step.
Table 3: Example of covariate data generated in Step 2.
Subject ID Time Male Age BMI Triglycerides Current exposure to
Abacavir (yes/no)
1 1 1 25 21.8 85 1
1 2 1 25 21.7 95 0
. . .
1 200 1 25 22.3 87 1
2 1 0 50 30.4 110 0
2 2 0 50 32.1 118 0
. . .
2 200 0 50 29.6 130 0
. . .
4.1.3 Step 3: Simulation of Categorical Variables
Simulating a categorical variable such as race with 3 categories posed a special challenge.
Simply including dummy variables to represent a multi-level categorical variable in the
simulation step with the other binary and continuous covariates does not preserve the
inherent collinearity of these variables. An obvious option is to jointly simulate all but
one reference level of the indicator variable for race, but such a strategy may limit con-
trol over marginal probabilities and it would not preclude a subject’s having more than
one race. Therefore, rather than simulating the categorical variables representing race
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jointly with the other covariates, we simulated it via a multinomial model as a function
of “baseline” covariates or those covariates that describe the subject at the first time of
observation. We used “baseline” covariates because our approach was to include a mutu-
ally exclusive categorical variable that was static. However, one could easily extend this
to simulate a mutually exclusive categorical variable that is time-varying by deriving the
term as a function of time-varying covariates. The parameters for these models were in-
formed by the motivating data set.
4.2 Simulation of Time-Dependent Outcome
For realism, we specified the distribution of the simulated survival times to closely re-
semble that of the observed. The algorithm uses a unit-less time measurement allowing
for flexibility in the number of time points generated. This number should be sufficiently
large to allow for granularity while not posing computational limitations. In the motivat-
ing data set, we observed a maximum time of 5112 days. However, for practical reasons
we chose to only simulate data with 200 time points. To ensure comparable distributions
of survival times in our motivating and simulated data sets, we rescaled the event times
in our motivating data set by dividing each observed time by 200 (5112 / 200 = 25.5).
After scaling, each event time was rounded up to the nearest integer, resulting in an ap-
propriately scaled version of the event times from our motivating data set. The distribu-
tion of these scaled event times was used to construct a probability mass function (PMF)
that corresponds to the desired event times. The PMF is a non-parametric distribution
of the survival times in the original population. For each simulated data set, we sampled
with replacement from this PMF to obtain N=2000 survival times. Censoring times were
generated from a uniform distribution with parameters chosen so that 40% of observa-
tions were censored. These survival and censoring times were used in Steps 1 and 2 of the
algorithm used for outcome generation, respectively, described in Section 3.2 and depicted
in Figure 2.
5 Results
We generated 2000 replications with 200 observations for each of 2000 subjects. In Ta-
bles 4 and 5, we present how closely our simulations match the motivating data set with
regard to distributional properties by showing the empirical values (from the motivating
data set), the average estimates across the 2000 replications (simulated), and the differ-
ence between the empirical and simulated quantities, for exposure variables (Table 4) and
covariates (Table 5). For the 15 binary variables representing drug exposure (proportion
exposed), the distance from the empirical values to the simulated quantities ranged from
0 (for 5 out of the 15 drugs) to 0.016. Differences between the empirical and average es-
timates for the proportion of records with exposure ranged in absolute value from 0.036
for the drug with lowest proportion (Saquinavir; true=0.04) to 0.13 for the drug with the
largest proportion (Lamivudine; true=0.4) (Table 4). Accuracy of covariates depended on
whether the variable was generated as time-varying or fixed at baseline. We found that
the algorithm generated fixed covariates with minimal differences between empirical and
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average estimated values (0 for the proportion of male sex, 0.109 for white race, 0.114 for
black race and 0.003 for race other, and 0.008 for mean age and -0.012 for age standard
deviation) while results for time-varying covariates were more variable. The algorithm
generated data with means that were close to the empirical means (absolute distance
from empirical value ranged from 0 for triglycerides to 0.208 for CD4 count). However,
the generated time-varying data had standard deviations that were farther from the em-
pirical standard deviations (on average) (Table 5).
Table 4: Accuracy results for the exposures: proportion of patients who are exposed to a
drug (“Proportion exposed”) and proportion of records where a drug is prescribed (“Pro-
portion of records with exposure”).
Drug Empirical Average Distance from
Value estimate empirical value
Proportion exposed
Abacavir 0.275 0.291 0.016
Atazanir 0.222 0.223 0.001
Didanosine 0.198 0.198 0
Efavirenz 0.500 0.500 0
Emtricitabine 0.413 0.413 0
Indinavir 0.206 0.214 0.008
Lamivudine 0.688 0.673 -0.015
Lopinavir 0.253 0.254 0.001
Nelfinavir 0.240 0.244 0.004
Nevirapine 0.184 0.185 0.001
Ritonavir 0.180 0.180 0
Saquinavir 0.103 0.105 0.002
Stavudine 0.332 0.334 0.002
Tenofovir 0.526 0.526 0
Zidovudine 0.544 0.543 -0.001
Proportion of records with exposure
Abacavir 0.12 0.033 -0.087
Atazanir 0.08 0.018 -0.062
Didanosine 0.09 0.018 -0.072
Efavirenz 0.16 0.080 -0.080
Emtricitabine 0.11 0.046 -0.064
Indinavir 0.07 0.015 -0.055
Lamivudine 0.40 0.270 -0.13 0
Lopinavir 0.12 0.031 -0.089
Nelfinavir 0.08 0.020 -0.060
Nevirapine 0.07 0.013 -0.057
Ritonavir 0.05 0.009 -0.041
Saquinavir 0.04 0.004 -0.036
Stavudine 0.17 0.058 -0.112
Tenofovir 0.22 0.116 -0.104
Zidovudine 0.24 0.131 -0.109
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Plots of simulated trajectories for two time-varying variables (changing over time within
a patient; A: BMI, B: LDL) for selected patients are shown in Supplemental Figure S1.
These plots illustrate that the algorithm generated time-varying covariates with realistic
trajectories with different levels of variability over time depending on the characteristics
imposed and as expected. Plots depicting the correlation among variables in the gener-
ated data (Supplemental Figure S2, right) and correlations present in the motivating data
set (Supplemental Figure S2, left) are shown in Supplemental Figure S2 and showed a
comparable correlation structure, as desired.
Table 5: Accuracy results for fixed/time-varying covariates.
Covariate Empirical Average Distance from
value estimate empirical value
Male p 0.97 0.97 0
Race
white p 0.338 0.447 0.109
black p 0.424 0.538 0.114
other p 0.012 0.015 0.003
Age µ 46 46.008 0.008
σ 10.12 10.108 -0.012
BMI µ 25 25.003 0.003
σ 4.2 4.974 0.774
CD4 Count µ 308.09 307.882 -0.208
σ 241.54 278.859 37.319
Systolic BP µ 126.85 126.866 0.016
σ 15.48 17.876 2.396
Diastolic BP µ 76.7 76.703 0.003
σ 9.96 11.502 1.542
0
LDL µ 99.1 99.104 0.004
σ 23 27.206 4.206
HDL µ 39.02 39.012 -0.008
σ 7 9.004 2.004
Triglycerides µ 180.87 180.87 0
σ 30 34.632 4.632
p, proportion; µ, mean; σ, standard deviation; BP, blood pressure
The distributions of the right-censored outcome between the empirical and simulated data
sets were also comparable. Figure 3 depicts the two distributions for one simulated data
13
Figure 3: Distribution of time to event in the real data (empirical) and simulated data.
p-value for Chi-square test comparing the two distributions equaled to 0.3.
set (p-value for Chi-square test comparing the two distributions = 0.3). Accuracy and
precision measures based on the parameters used in the generation of survival times are
shown in Table 6. Average estimates across the 2000 replications were close to the true
or targeted values, leading to relative and standardized biases that are negligible. RMSE
values appear to be very small and coverage probabilities are all close to the nominal level
of 95%.
6 Application – Simulation Tool for Designing Compara-
tive Effectiveness Studies
Off-the-shelf power calculators aid in designing studies by estimating the power (or sam-
ple size needed) for a single hypothesis test through closed-form equations that typically
make an assumption about the relationship between one variable of interest and outcome.
Our simulation tool, however, provides the flexibility to estimate other quantities, such as
the probability of detecting a group of effects, while simultaneously allowing the inclusion
of a more realistically complex set of features.
We provide the following illustration of the utility of our method for a power calculation
addressing a complex set of questions. Suppose investigators are interested in doing a
comparative effectiveness study of HIV medications and have access to published data of
a source such as the CCR. This information can be used to determine the power to iden-
tify which drug exposures of the 15 drugs considered are associated with cardiovascular
14
Table 6: Accuracy and precision measures in the generation of right-censored outcome.
True Estimated log-hazard ratio
log-hazard ratio Mean Bias Avg. SE Std. Bias MSE Coverage
Indicator of drug exposure
Abacavir 0.7 0.686 -0.014 0.119 -12 0.0145 95%
Atazanir 0.5 0.484 -0.016 0.175 -9 0.0326 95%
Didanosine 0.3 0.285 -0.015 0.194 -8 0.0344 96%
Efavirenz 0 -0.005 -0.005 0.108 -5 0.0116 95%
Emtricitabine 0 -0.009 -0.009 0.148 -6 0.0229 95%
Indinavir 0 -0.026 -0.026 0.228 -11 0.0556 94%
Lamivudine 0.5 0.495 -0.005 0.070 -8 0.0050 95%
Lopinavir 0 -0.015 -0.015 0.166 -9 0.0284 95%
Nelfinavir 0 -0.011 -0.011 0.194 -6 0.0379 96%
Nevirapine 0 -0.029 -0.029 0.237 -12 0.0615 95%
Ritonavir 0 -0.040 -0.040 0.301 -13 0.0969 96%
Saquinavir 0 -0.079 -0.079 0.438 -18 0.2199 96%
Stavudine 0 -0.005 -0.005 0.122 -4 0.0143 95%
Tenofovir 0 -0.005 -0.005 0.097 -5 0.0088 96%
Zidovudine 0 -0.002 -0.002 0.088 -2 0.0081 95%
Covariates
Male 0.15 0.138 -0.012 0.192 -6 0.0381 95%
Race
White Reference
Black -0.2 -0.202 -0.002 0.060 -4 0.0034 96%
Other 0 -0.026 -0.026 0.247 -11 0.0693 95%
Age 0.02 0.02 0 0.003 -13 0 95%
BMI
< 20 2 1.971 -0.029 0.088 -33 0.0096 91%
20− 25 Reference
25− 30 0 -0.002 -0.002 0.089 -2 0.0081 94%
> 30 2 1.972 -0.028 0.089 -32 0.0096 93%
CD4 Count
< 50 Reference
50− 100 0.15 0.148 -0.002 0.156 -1 0.0261 94%
100− 200 -0.06 -0.057 0.003 0.119 2 0.0159 94%
200− 350 0.03 0.026 -0.004 0.103 -4 0.0112 94%
350− 500 -0.06 -0.065 -0.005 0.091 -5 0.0092 94%
Blood Pressure
Systolic 0.005 0.005 0 0.003 -4 0 95%
Diastolic 0.005 0.005 0 0.002 -3 0 95%
Cholesterol
LDL 0.005 0.005 0 0.001 -12 0 93%
HDL 0.002 0.002 0 0.004 -2 0 94%
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events in the presence of multiple time-varying confounders including the drug exposures.
To illustrate, we assumed that some drugs (5) were associated with cardiovascular events
with varying magnitudes of association, and that some were not. Suppose the range of
association was from modest to high magnitudes with log-hazards ranging from 0.05 to
0.7 (or hazard ratios ranging from 1.05 to 2.0), and with varying frequencies of exposure,
where the latter was informed by the empirical data set. We further assumed that the
number of cardiovascular events was unknown but anticipated to be relatively low accord-
ing to external data (occurring at a rate of 5%). A simulation was performed that gener-
ated 100 data sets with 20,000 subjects each and 150 observations per subject, with the
following characteristics:
1. Exposures: 15 drugs
1.1. 50% of patients were exposed to each of the 15 drugs
1.2. 5 drugs were positively associated with outcome where prevalences of exposure
are: 0.05, 0.1, 0.2, 0.3, and 0.4
1.3. The remaining10 drugs were not associated with outcome and were generated
with a prevalence of 0.2
2. Covariates: All other covariates were generated using distributional properties in-
formed by the motivating data set
3. Outcome: time to cardiovascular disease
3.1. Time to cardiovascular disease was drawn from a Weibull distribution with pa-
rameters κ = 1.5 (shape) and λ = 76.6 (scale) for a median time-to-cardiovascular-
event of 60 months
3.2. Censoring times were drawn from a Weibull distribution, with parameters κ =
1 (shape) and λ = 10 (scale) to produce 95% censoring
3.3. Associations between other confounders and outcome were assumed to have
characteristics as those described in Table 6
3.4. The 5 main drugs were assigned an effect that corresponded to hazard ratios
(HRs) of 1.05, 1.15, 1.20, 1.50, and 2.00. The corresponding coefficients were
permuted with drug prevalence resulting in 120 (5!) arrangements of the effects
across the 5 drugs.
3.5. The remaining 10 drugs were assumed to be unassociated with outcome with
corresponding HRs of 1.0.
To illustrate, for each possible permutation of effects, we generated 100 data sets and fit
a Cox frailty model to each, assuming a varying baseline hazard for each patient, thus
taking into account that each patient has multiple observations, due to changes in medi-
cation regimen. Using the simulated data sets, we computed the probability of detecting
associations between outcome and all 5 drugs, the probability of detecting at least one
association, as well as the probability of falsely detecting an association.Tests were con-
ducted at the .05/15=0.003 level to account for multiplicity.
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For comparison, we also computed the power using two standard software packages avail-
able in Stata: stpower cox and stpower exponential. stpower cox assumes a Cox propor-
tional hazards model and allows one to incorporate the expected correlation between
the drug being tested and other covariates that will be included in the Cox PH model.
stpower exponential assumes that the survival times are exponentially distributed and
that the observations are independent and no confounding is present. For the former, we
assumed a correlation between the drug of interest and other covariates of 0.2 on a data
set with a sample size of 20,000. For both calculations, we assumed that each patient had
one single record that contained both an indicator for drug use and outcome. Similar to
the simulation, we conducted separate hypothesis tests on each of the 15 drug coefficients,
each at the 0.003 level of significance.
6.1 Results from the Power Calculation Using the Simulation Tool
The simulation shows that with 20,000 subjects, we had little power to detect all asso-
ciations of interest (0.00017). Even though the mean number of drugs detected across
all data sets was 2.38, the probability of detecting associations with 2 drugs was only
0.6. As expected, the power decreased for drugs with lower prevalences. For a drug with
a prevalence of 20%, there was less than 40% power to detect a hazard ratio of 1.2 but
100% power to detect a hazard ratio of 1.5. For the lowest prevalence assumed (5%), the
power to detect a hazard ratio of 1.5 was 71%. We observed similar results for the power
to detect each drug individually using the stpower cox command, however, the stpower
exponential command gave discrepant results, reporting lower power overall. Agreement
in results across all 3 methods increased as exposure prevalence increased (Figure 4). Im-
portantly, our simulation tool allowed evaluation of joint discoveries (Figure 4, bottom
right panel) whereas the traditional tools do not yield such results.
7 Discussion
Simulation studies provide a means to evaluate methods, particularly when theoretical de-
scriptions of statistical properties of estimators are not feasible [14, 15, 16, 17, 18]. For
example, statistical properties of estimators may be well characterized only when the
sample size reaches asymptotic levels, but have unknown behavior for smaller sample sizes
[19, 20]. Such studies are increasing in importance in the current era of big data, where
complexities such as an unknown correlation structure of a large number of features may
affect method performance and may be difficult to characterize theoretically [21]. Simu-
lation studies where the true data generating model is known are critical for evaluating
performance of models that are commonly applied but that may not match the true gen-
erating model.
We have created a comprehensive algorithm that makes use of an external data resource
to generate an entire study where a right-censored outcome is a function of multiple cor-
related time-varying covariates of mixed type. We have demonstrated that empirical es-
timates of the generated data are comparable to those of the external data source, sug-
gesting the algorithm successfully captures the complexities of the data set. In addition,
17
Figure 4: Comparison of power calculation using the simulation tool and Stata commands
stpower cox (Cox PH r2=0.2; assuming correlation between covariates to be equal to 0.2)
and stpower exponential for varying prevalences and hazard ratios
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we have provided open-source software that call existing R packages such as binnor. This
approach allows other investigators to implement our algorithm, and further enhance it or
tailor it for their own purposes. Our algorithm captures multiple complexities of an exist-
ing longitudinal data set that includes correlation across features as well as correlation of
a given feature within a subject or cluster.
There are limitations to our approach. Because variables containing proportions (bounded
between 0 and 1) are generated from the normal distribution, further adjustments are
necessary. Specifically, after generating data that describes whether a subject is ever ex-
posed to a drug using marginal information, the algorithm includes steps to ensure in-
dividual proportions are between 0 and 1 as would be desired for such a variable. This
intermediate step could have been avoided had we simulated from the Beta distribution.
However, there is no existing way to simulate Beta random variables jointly with Bino-
mially and Normally distributed random variables. In addition, generating categorical
variables that contain more than 2 levels was challenging. We solved this by generating
the categorical variable using a multinomial model after generating all binary and contin-
uous characteristics. An alternative approach is to stratify by levels of the covariate and
simulate within each level. Our method is more desirable, however, in that it can be ex-
tended to accommodate additional categorical variables by fitting a series of multinomial
models in a sequential fashion. When simulating a study, it may be desirable to use the
existing covariates of a data set and only simulate the outcome, as the correlation struc-
ture of the features will be captured. However, that is not always feasible for two reasons:
1) The raw data may not be available to be fully used in the simulations; and 2) One may
also need to vary parameters involved in the covariate generation. Making use of an ex-
ternal data source may still be possible, however, by incorporating information about the
marginal and joint distribution of key features in order to capture the essence of the com-
plexities of the data set. For example, if interested in methods for drawing causal infer-
ence in the presence of confounding, one could impose interrelationships among variables
that represent confounding while maintaining marginal distributions of the characteris-
tics.
Code for implementing our simulation tool, SimulateCER, is currently available. Effort
to submit the R package to the Comprehensive R Archive Network (CRAN) is ongoing.
However, it can immediately be downloaded from github (https://github.com/qsuProjects/SimulateCER).
We have created vignettes that demonstrate the use of the algorithm and these can be
found here: https://github.com/qsuProjects/SimulateCER/tree/master/R/GENCOV/vignettes.
In order to use the algorithm, there are a set of parameters that need to be defined and
data sets that need to be provided with information related to each variable to be gen-
erated: (1) A matrix listing the type (ID variable, normal variable corresponding to the
mean proportion for a binary time-varying variable, other normal variable, time-function
continuous variable, binary time-varying variable, or binary static variable) of each vari-
able and relevant parameters (e.g., the across-subject mean and variance and the within-
subject variance for normal variables); (2) An across-subject correlation matrix; and, (3)
A within-subject correlation matrix.
Our code recognizes if some components are not well-defined and adapts them so that
data are generated as intended. For example, there are theoretical bounds on the max-
imum absolute correlation between a normal and a binomial variable depending on the
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population proportion for the latter. If the user specifies an implausible correlation for
two such variables, the code will automatically adjust the correlation and provide a warn-
ing. Additionally, if the user does not provide within-subject variances for the normal
variables, these will default to 1/3 of the corresponding across-subject variances. Finally,
the code flexibly accommodates generation of data in arbitrary combinations of variable
types. For example, any number of each variable type can be generated simultaneously
(as long as there is at least one continuous and one binary variable). To omit one or more
types of variables, the user can simply omit parameters for such variables in the param-
eters spreadsheet (e.g., time-function variables will not be generated in the absence of
slope parameters).
We have demonstrated a simulation to determine power using our algorithm. Mainstream
software packages that calculate power to address a variety of research questions in the
presence of a large number of correlated features and small sample sizes do not exist.
Currently, power calculation formulas allow the inclusion of a single correlation coefficient
relating one exposure to other covariates. This only applies, however, to the case where
there are time-invariant covariates and not multiple observations per subject. Simulation
studies can be helpful here, where we can evaluate the power in the presence of multiple
time-varying characteristics with varying correlation. In addition, we can evaluate the
precision to assess predictive ability of a decision rule, the probability of identifying all
relevant features in a molecular signature, the power of identifying at least one character-
istic associated with outcome, and the power of identifying an exact number of character-
istics that are associated with the outcome (with varying magnitudes of association). To
facilitate access to the simulation-based power calculations, our team is developing a user-
friendly interface using the Shiny package in R but code can already be accessed through
github (https://github.com/qsuProjects/CERPower). Our team’s original motivation for
simulation scenarios, however, was to evaluate missing data approaches in the longitudi-
nal setting in the presence of time-varying covariates and right-censored outcomes, which
provides another example of use of such studies.
In the example we looked at, from our power calculations that relied on our algorithm to
simulate data, we found that we had 80% power to detect HRs of 1.5 and higher if the
exposure prevalence was 10% or higher. The power was lower if the exposure prevalence
was 5%. Additionally, given 5 exposures that were associated with outcome (with vary-
ing magnitudes), we would very likely not be able to detect all of them, and we had only
a 34% probability of identifying 3 of the 5 drug exposures as being of interest. In con-
trast, the power calculations derived from stpower cox could only describe the power of
detecting one exposure given a certain association. When prevalence of the exposure was
40% and with a high level of clustering, stpower cox ’s estimated power was lower than
what we obtained using our simulations but similar to the power obtained using stpower
exponential. To summarize, there are three main differences between the simulation that
demonstrated power and stpower cox : 1) Using the command stpower one cannot summa-
rize statistics such as probability of detecting at least one or probability of detecting all 5;
2) The stpower cox analysis assumes that each patient has one single record with no time-
varying variables; and 3) While in stpower cox one needs to summarize the correlation
between exposure and covariates into one single value, that is not the case when using a
simulation.
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We have developed an algorithm that allows simulation of data from a study that can
capture multiple complexities of a real longitudinal data set. Our algorithm performs
well in that it can be used to closely resemble a desired external target and it can reflect
complexities observed in real CER studies. Further, it can easily be implemented using
the open-source software we have provided in R. We have shown that there are multiple
uses of our algorithm to develop or evaluate methods involving right-censored outcomes
that are functions of time-static and time-varying covariates that are correlated with each
other and within a subject over time.
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Supplemental Figure S1. Plots of simulated trajectories of variables that change over time 
for selected subjects 
 
A: BMI 
 
B: LDL 
 
 
   6   64  188  197  229
 276  286  402  523  587
 653  688  846 1131 1219
1353 1409 1446 1557 1913
15
20
25
30
35
15
20
25
30
35
15
20
25
30
35
15
20
25
30
35
0 50 100 150 0 50 100 150 0 50 100 150 0 50 100 150 0 50 100 150
Time
BM
I
  76  294  483  550  553
 649  853  962 1091 1222
1259 1285 1460 1530 1669
1699 1734 1792 1876 1998
30
60
90
120
150
30
60
90
120
150
30
60
90
120
150
30
60
90
120
150
0 50 100 150 200 0 50 100 150 200 0 50 100 150 200 0 50 100 150 200 0 50 100 150 200
Time
LD
L
24
Supplemental Figure S2.  Correlation matrix plot of empirical correlations (left) and of averaged simulation-based correlations (right).  
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